A Phase IIIb, Multicenter, Randomized, Visual Assessor-Masked Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 17 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ranibizumab (Primary) ; Aflibercept
Indications Age-related macular degeneration
Focus Registrational; Therapeutic Use
Acronyms Diagrid
Sponsors Roche

Most Recent Events

17 Apr 2024 This trial has been completed in Portugal, according to European Clinical Trials Database record.
13 Apr 2024 This trial has been Completed in Germany (Global end date : 8 Jan 2024), according to European Clinical Trials Database record.
08 Apr 2024 This trial has been Completed in Austria (Global end date : 8 Jan 2024).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight